Skip to main content

Table 2 Patient characteristics

From: Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer

Patient characteristics   n = 35
Sex   male;28 : female;7 (80 %:20 %)
Age   65.7 ± 5.7
Performance status (ECOG) 0 3 (8.6 %)
1 32 (91.4 %)
Histology Small cell carcinoma 17 (48.6 %)
Adenocarcinoma 12 (34.3 %)a
Squamous carcinoma 3 (8.6 %)
Pleural mesothelioma 2 (5.7 %)
Large cell carcinoma 1 (2.9 %)
Clinical stage (UICC TNM) I B 1 (2.9 %)
IIA 2 (5.7 %)
IIB 1 (2.9 %)
IIIA 6 (17.1 %)
IIIB 3 (8.6 %)
IV 21 (60.0 %)
Unknown 1 (2.9 %)
Smoking status Never 6 (17.1 %)
Ever 11 (31.4 %)
Current 18 (51.4 %)
CDDP dosage (mg/m2)   69.7 ± 8.9
CDDP cumulative dosage (mg/m2)   278.6 ± 63.3
Course   4.1 ± 0.9
CDDP dose reduction (%) None 21 (60 %)
1 stage reduction 8 (23 %)
2 stage reduction 6 (17 %)
Regimen CDDP + MTA ± BV 12 (34 %)
CDDP + VP-16 12 (34 %)
CDDP + CPT-11 5 (14 %)
CDDP + GEM 5 (14 %)
CDDP + DTX 1 (4 %)
Hydration volume (mL) 1937 ± 193
Infusion time (hr) 4.8 ± 1.1
Renal function sCre (mg/dL) 0.7 ± 0.1
BUN (mg/dL) 14.3 ± 3.8
Adjusted eGFR (mL/min) 79.8 ± 9.9
  1. mean ± SD
  2. a Driver mutation status; Epidermal Growth Factor Receptor; EGFR (+); n = 2, Anaplastic lymphoma kinase; ALK (+); n = 1